Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 13 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-0.91 Insider Own14.36% Shs Outstand35.17M Perf Week-0.11%
Market Cap634.72M Forward P/E29.73 EPS next Y0.60 Insider Trans3.65% Shs Float30.30M Perf Month10.47%
Income-31.33M PEG- EPS next Q-0.18 Inst Own58.22% Short Float14.14% Perf Quarter76.23%
Sales138.68M P/S4.58 EPS this Y28.33% Inst Trans-4.54% Short Ratio7.99 Perf Half Y88.45%
Book/sh1.70 P/B10.56 EPS next Y212.25% ROA-12.23% Short Interest4.28M Perf Year-13.29%
Cash/sh2.15 P/C8.35 EPS next 5Y15.00% ROE-76.44% 52W Range7.60 - 22.63 Perf YTD60.18%
Dividend Est.- P/FCF99.64 EPS past 5Y- ROI-12.49% 52W High-20.72% Beta0.75
Dividend TTM- Quick Ratio2.73 Sales past 5Y27.34% Gross Margin69.77% 52W Low136.05% ATR (14)0.93
Dividend Ex-Date- Current Ratio2.99 EPS Y/Y TTM-40.50% Oper. Margin-5.28% RSI (14)64.36 Volatility4.45% 5.44%
Employees315 Debt/Eq3.19 Sales Y/Y TTM49.79% Profit Margin-22.59% Recom1.00 Target Price28.15
Option/ShortYes / Yes LT Debt/Eq3.18 EPS Q/Q-74.37% Payout- Rel Volume0.34 Prev Close18.25
Sales Surprise-4.77% EPS Surprise-74.71% Sales Q/Q32.50% EarningsMay 13 AMC Avg Volume536.20K Price17.94
SMA202.67% SMA5028.49% SMA20044.67% Trades Volume181,687 Change-1.70%
Date Action Analyst Rating Change Price Target Change
Apr-11-24Initiated Craig Hallum Buy $24
Sep-08-22Resumed B. Riley Securities Buy $17
Oct-14-21Resumed B. Riley Securities Buy $16
Sep-24-21Initiated Aegis Capital Buy $15
Jul-02-21Initiated Ladenburg Thalmann Buy $14.25
Jun-07-24 06:30AM
Jun-06-24 08:00AM
Jun-05-24 07:00AM
May-15-24 07:00AM
May-13-24 08:55PM
04:25PM Loading…
Apr-25-24 07:00AM
Apr-02-24 08:16AM
Mar-21-24 09:55AM
Mar-19-24 09:52PM
Mar-13-24 06:35AM
07:00AM Loading…
Mar-05-24 07:00AM
Mar-04-24 08:28PM
Feb-21-24 06:47AM
Feb-15-24 04:01PM
Jan-29-24 07:00AM
Jan-11-24 07:00AM
Jan-03-24 07:15AM
Dec-24-23 01:08PM
Nov-29-23 07:00AM
Nov-20-23 07:00AM
Nov-14-23 12:56PM
Nov-13-23 05:07PM
Oct-30-23 08:00AM
07:00AM Loading…
Oct-24-23 07:00AM
Sep-29-23 08:00AM
Sep-26-23 08:00AM
Sep-21-23 01:03PM
Aug-11-23 01:05PM
Aug-10-23 09:54AM
Aug-09-23 04:14PM
Jul-31-23 07:00AM
Jul-28-23 02:56PM
Jul-26-23 03:42PM
Jul-20-23 10:29AM
Jul-19-23 12:17PM
Jul-18-23 05:00PM
Jul-05-23 06:15PM
Jun-29-23 06:15PM
Jun-23-23 06:15PM
Jun-16-23 06:00PM
May-17-23 08:00AM
May-16-23 11:57AM
May-15-23 11:21AM
May-12-23 01:48PM
May-11-23 05:15PM
May-08-23 12:07PM
May-04-23 08:00AM
May-03-23 06:44AM
May-02-23 04:42PM
May-01-23 08:50AM
Apr-28-23 06:00PM
Apr-27-23 08:05AM
Apr-24-23 08:43AM
Apr-20-23 08:31AM
Apr-19-23 06:15PM
Apr-18-23 06:24AM
Apr-14-23 08:50AM
Apr-13-23 06:15PM
Apr-12-23 09:40AM
Apr-09-23 04:04PM
Apr-05-23 09:34AM
Apr-04-23 05:37AM
Apr-03-23 06:53AM
Mar-29-23 08:50AM
Mar-28-23 02:59PM
Mar-27-23 08:51AM
Mar-24-23 05:42AM
Mar-23-23 04:06PM
Mar-13-23 07:00AM
Mar-06-23 08:00AM
Mar-02-23 08:00AM
Feb-16-23 06:42AM
Feb-15-23 07:00AM
Feb-03-23 08:50AM
Feb-02-23 06:30AM
Jan-23-23 07:00AM
Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Opaleye Management Inc.10% OwnerApr 25 '24Buy9.9720,000199,4003,815,000Apr 25 05:19 PM
Opaleye Management Inc.10% OwnerApr 24 '24Buy10.158,28584,0933,795,000Apr 24 04:40 PM
Opaleye Management Inc.10% OwnerApr 23 '24Buy10.2911,715120,5473,786,715Apr 24 04:40 PM
Opaleye Management Inc.10% OwnerApr 19 '24Buy10.5629,400310,3903,775,000Apr 19 06:24 PM
Opaleye Management Inc.10% OwnerMar 28 '24Buy12.8250,000641,0003,745,600Mar 28 06:07 PM
BAUM MARK LCHIEF EXECUTIVE OFFICERMar 22 '24Buy11.599,000104,3102,137,525Mar 25 07:00 AM
Opaleye Management Inc.10% OwnerMar 20 '24Buy9.6550,600488,2903,695,600Mar 22 11:52 AM
SAHAREK JOHN P.CEO of ImprimisRxMar 01 '24Option Exercise8.755,00043,750254,803Mar 06 06:06 AM
BAUM MARK LCHIEF EXECUTIVE OFFICERFeb 20 '24Option Exercise10.67150,0001,600,5002,188,361Feb 21 07:29 PM
BOLL ANDREW R.CHIEF FINANCIAL OFFICERFeb 20 '24Option Exercise10.6745,000480,150586,569Feb 21 07:29 PM
SAHAREK JOHN P.CEO of ImprimisRxFeb 20 '24Option Exercise10.6730,000320,100262,419Feb 21 07:30 PM
BAUM MARK LCHIEF EXECUTIVE OFFICERFeb 07 '24Option Exercise7.7115,400118,7342,038,361Feb 08 07:30 AM
BOLL ANDREW R.CHIEF FINANCIAL OFFICERFeb 07 '24Option Exercise7.717,40057,054541,569Feb 08 07:30 AM
BAUM MARK LChief Executive OfficerNov 16 '23Buy8.117,50060,8252,022,961Nov 16 04:45 PM
Opaleye Management Inc.10% OwnerNov 15 '23Buy8.0325,000200,7353,645,000Nov 16 04:05 PM
Opaleye Management Inc.10% OwnerSep 20 '23Buy14.495,98386,7103,620,000Sep 20 06:39 PM
Opaleye Management Inc.10% OwnerSep 19 '23Buy14.6514,017205,3663,614,017Sep 20 06:39 PM
Makary Martin A.DirectorAug 14 '23Buy16.9220,000338,40045,000Aug 15 07:30 AM
BAUM MARK LChief Executive OfficerAug 14 '23Buy17.055,80098,8902,015,461Aug 15 07:30 AM
Last Close
Jun 13 04:00PM ET
Dollar change
Percentage change
TCON TRACON Pharmaceuticals Inc daily Stock Chart
Index- P/E1.50 EPS (ttm)0.65 Insider Own6.70% Shs Outstand2.68M Perf Week-17.80%
Market Cap2.60M Forward P/E- EPS next Y-2.86 Insider Trans0.00% Shs Float2.50M Perf Month-50.76%
Income1.75M PEG- EPS next Q-1.41 Inst Own5.96% Short Float4.76% Perf Quarter-88.92%
Sales12.14M P/S0.21 EPS this Y-89.70% Inst Trans-0.73% Short Ratio0.45 Perf Half Y-70.61%
Book/sh-0.66 P/B- EPS next Y31.39% ROA19.78% Short Interest0.12M Perf Year-91.02%
Cash/sh2.94 P/C0.33 EPS next 5Y- ROE- 52W Range0.66 - 14.75 Perf YTD-72.30%
Dividend Est.- P/FCF0.42 EPS past 5Y61.51% ROI- 52W High-93.42% Beta1.22
Dividend TTM- Quick Ratio0.80 Sales past 5Y-40.00% Gross Margin99.88% 52W Low46.97% ATR (14)0.20
Dividend Ex-Date- Current Ratio0.80 EPS Y/Y TTM102.58% Oper. Margin-23.03% RSI (14)25.22 Volatility19.79% 11.23%
Employees17 Debt/Eq- Sales Y/Y TTM-100.00% Profit Margin14.39% Recom1.67 Target Price30.50
Option/ShortNo / Yes LT Debt/Eq- EPS Q/Q81.52% Payout- Rel Volume0.61 Prev Close1.00
Sales Surprise- EPS Surprise-11.76% Sales Q/Q- EarningsMay 14 AMC Avg Volume265.23K Price0.97
SMA20-27.56% SMA50-50.43% SMA200-73.69% Trades Volume161,700 Change-2.99%
Date Action Analyst Rating Change Price Target Change
Apr-16-21Upgrade BTIG Research Neutral → Buy $14
Feb-10-21Initiated Maxim Group Buy $24
Dec-23-19Reiterated H.C. Wainwright Buy $15 → $18
Mar-01-19Reiterated Needham Buy $7
Jun-13-17Reiterated Stifel Buy $14 → $6
Dec-21-16Initiated Jefferies Buy $10
Feb-01-16Resumed Oppenheimer Outperform
Jul-29-15Initiated ROTH Capital Buy $18
Mar-02-15Reiterated Stifel Buy $16 → $20
Mar-02-15Reiterated Oppenheimer Outperform $22 → $26
Jun-11-24 08:00AM
May-15-24 06:53AM
May-14-24 08:56PM
04:01PM Loading…
May-07-24 04:01PM
Apr-10-24 06:30AM
Apr-08-24 09:10AM
Apr-03-24 08:00AM
Mar-07-24 10:03AM
Mar-05-24 04:29PM
Feb-28-24 04:02PM
Dec-20-23 08:00AM
07:55AM Loading…
Nov-21-23 07:55AM
Nov-20-23 08:00AM
Nov-13-23 09:29AM
Nov-12-23 08:47AM
Nov-10-23 07:45AM
Nov-09-23 04:58PM
Oct-31-23 04:02PM
Sep-18-23 08:00AM
Sep-05-23 04:02PM
Aug-25-23 07:20AM
Aug-15-23 08:43AM
Aug-14-23 07:00PM
04:05PM Loading…
Aug-02-23 04:05PM
Jul-11-23 08:00AM
Jun-20-23 08:00AM
Jun-16-23 08:00AM
Jun-15-23 08:00AM
Jun-02-23 08:00AM
May-30-23 08:00AM
May-11-23 11:24AM
May-10-23 04:38PM
May-03-23 04:02PM
Apr-25-23 07:41AM
Apr-06-23 08:30AM
Mar-14-23 12:00PM
Mar-10-23 02:26AM
Mar-09-23 05:49AM
Mar-08-23 04:02PM
Feb-28-23 04:02PM
Jan-20-23 06:55AM
Jan-10-23 08:30AM
Dec-27-22 08:00AM
Dec-14-22 11:29AM
Nov-21-22 08:00AM
Nov-14-22 04:02PM
Oct-31-22 08:00AM
Oct-06-22 08:30AM
Sep-14-22 08:00AM
Sep-07-22 08:00AM
Sep-06-22 08:00AM
Aug-29-22 08:00PM
Aug-10-22 04:02PM
Aug-08-22 08:00AM
Jul-27-22 08:05AM
Jul-26-22 08:05AM
Jun-02-22 08:05AM
May-16-22 08:05AM
May-11-22 04:02PM
May-04-22 08:05AM
Apr-19-22 08:05AM
Apr-08-22 05:02PM
Mar-23-22 08:05AM
Mar-15-22 04:02PM
Mar-11-22 08:05AM
Mar-10-22 08:05AM
Mar-04-22 08:05AM
Feb-02-22 08:05AM
Jan-05-22 08:05AM
Dec-27-21 08:00AM
Nov-29-21 08:05AM
Nov-11-21 08:05AM
Nov-03-21 04:02PM
Oct-27-21 08:05AM
Oct-13-21 08:00AM
Oct-11-21 01:27PM
Sep-13-21 08:05AM
Sep-07-21 08:05AM
Sep-02-21 08:05AM
Aug-11-21 04:02PM
Aug-09-21 08:05AM
Aug-03-21 08:05AM
Jul-28-21 08:05AM
Jul-21-21 10:30PM
TRACON Pharmaceuticals, Inc. engages in the development and commercialization of targeted therapies for cancer, and ophthalmic and fibrotic diseases. Its products include TRC105, an anti-endoglin antibody for the treatment of solid tumor types, TRC205 created for the treatment of fibrotic diseases, and TRC102, a small molecule that is in clinical development made for lung cancer and glioblastoma. The company was founded in October 2004 and is headquartered in San Diego, CA.
Last Close
Jun 13 04:00PM ET
Dollar change
Percentage change
TARA Protara Therapeutics Inc daily Stock Chart
Index- P/E- EPS (ttm)-3.74 Insider Own7.36% Shs Outstand20.59M Perf Week-3.69%
Market Cap53.74M Forward P/E- EPS next Y-3.65 Insider Trans-17.03% Shs Float19.07M Perf Month-21.86%
Income-42.47M PEG- EPS next Q-0.74 Inst Own43.16% Short Float8.28% Perf Quarter-26.89%
Sales0.00M P/S- EPS this Y-0.45% Inst Trans-2.32% Short Ratio3.92 Perf Half Y80.00%
Book/sh5.11 P/B0.51 EPS next Y-1.84% ROA-48.67% Short Interest1.58M Perf Year-6.79%
Cash/sh2.68 P/C0.97 EPS next 5Y- ROE-55.45% 52W Range1.04 - 5.24 Perf YTD39.19%
Dividend Est.- P/FCF- EPS past 5Y39.98% ROI-67.81% 52W High-50.19% Beta1.87
Dividend TTM- Quick Ratio10.53 Sales past 5Y0.00% Gross Margin- 52W Low150.96% ATR (14)0.25
Dividend Ex-Date- Current Ratio10.53 EPS Y/Y TTM34.41% Oper. Margin0.00% RSI (14)38.59 Volatility6.70% 9.29%
Employees27 Debt/Eq0.09 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price27.80
Option/ShortYes / Yes LT Debt/Eq0.07 EPS Q/Q-21.41% Payout- Rel Volume0.21 Prev Close2.65
Sales Surprise- EPS Surprise-5.43% Sales Q/Q- EarningsMay 02 BMO Avg Volume403.32K Price2.61
SMA20-10.54% SMA50-13.38% SMA2005.30% Trades Volume84,551 Change-1.51%
Date Action Analyst Rating Change Price Target Change
Jul-10-23Resumed Guggenheim Buy $22
Jun-04-21Initiated H.C. Wainwright Buy $40
Feb-17-21Initiated Oppenheimer Outperform $43
Oct-19-20Initiated Cowen Outperform $50
Jul-29-20Initiated Guggenheim Buy $50
May-21-24 08:00AM
May-02-24 12:54PM
Apr-12-24 09:55AM
Apr-05-24 08:04AM
08:02AM Loading…
Mar-13-24 08:00AM
Feb-28-24 08:00AM
Jan-31-24 07:30AM
Nov-30-23 08:30AM
Nov-03-23 09:43AM
Oct-23-23 08:00AM
Sep-20-23 08:30AM
07:30AM Loading…
Sep-05-23 07:30AM
Aug-03-23 08:00AM
May-15-23 08:00AM
May-04-23 08:00AM
May-02-23 08:00AM
Apr-28-23 08:00AM
Mar-08-23 08:00AM
Mar-01-23 08:00AM
Feb-02-23 08:00AM
Jan-30-23 08:00AM
Dec-01-22 08:00AM
Nov-03-22 08:00AM
Oct-24-22 08:35AM
Sep-06-22 08:00AM
Aug-09-22 08:00AM
08:00AM Loading…
Jun-21-22 08:00AM
May-26-22 05:11PM
May-17-22 08:00AM
May-12-22 08:00AM
May-05-22 08:00AM
Apr-11-22 09:55AM
Mar-24-22 08:00AM
Mar-23-22 10:00AM
Mar-09-22 07:30AM
Mar-08-22 05:50AM
Mar-02-22 08:00AM
Feb-01-22 08:00AM
Jan-10-22 08:00AM
Jan-04-22 08:00AM
Dec-08-21 11:15AM
Nov-04-21 08:00AM
Oct-25-21 04:45PM
Oct-12-21 07:00AM
Sep-17-21 04:05PM
Sep-13-21 07:00AM
Sep-09-21 10:31AM
Sep-07-21 08:00AM
Aug-05-21 08:00AM
Jul-07-21 08:00AM
Jun-22-21 07:30AM
Jun-10-21 08:00AM
May-13-21 08:00AM
May-06-21 07:30AM
Apr-23-21 07:00AM
Apr-19-21 04:09PM
Apr-12-21 11:12AM
Mar-30-21 07:01AM
Mar-11-21 07:30AM
Mar-10-21 08:00AM
Feb-04-21 08:00AM
Feb-02-21 08:00AM
Dec-16-20 11:07PM
Dec-07-20 04:30PM
Dec-03-20 07:00AM
Nov-24-20 07:00AM
Nov-12-20 07:15AM
Nov-11-20 07:00AM
Nov-04-20 07:00AM
Sep-28-20 03:12PM
Sep-22-20 08:13AM
Sep-21-20 04:01PM
Sep-08-20 07:00AM
Sep-02-20 05:49PM
Aug-03-20 07:00AM
Jul-28-20 07:00AM
Jul-24-20 07:00AM
Jul-03-20 06:34PM
Jul-02-20 07:59PM
Jun-02-20 04:05PM
May-26-20 08:30AM
May-13-20 08:00AM
May-11-20 08:38AM
May-05-20 04:05PM
Apr-02-20 07:00AM
Feb-11-20 08:00AM
Protara Therapeutics, Inc. is a clinical-stage company engaged in developing treatments for rare and specialty diseases with significant unmet needs. Its current development programs focus on the treatment of rare diseases in structural and connective tissues and rare hepatology, gastrointestinal, and metabolic disorders. The company was founded by Jesse Shefferman and Jacqueline Zummo in March 2006 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Opaleye Management Inc.10% OwnerMay 31 '24Sale2.905,82416,895108,696May 31 04:05 PM
Opaleye Management Inc.10% OwnerMay 30 '24Sale2.949,23027,113114,520May 31 04:05 PM
Opaleye Management Inc.10% OwnerMay 22 '24Sale3.029,80029,596123,750May 23 07:01 PM
Opaleye Management Inc.10% OwnerMay 21 '24Sale3.0633,000100,838124,250May 23 07:01 PM
Opaleye Management Inc.10% OwnerMay 17 '24Sale3.2570,885230,326126,050May 17 07:48 PM
Opaleye Management Inc.10% OwnerMay 10 '24Sale3.11151,700472,4242,380,294May 10 06:57 PM
Opaleye Management Inc.10% OwnerMay 09 '24Sale3.0930,60094,5262,531,994May 10 06:57 PM
Last Close
Jun 13 04:00PM ET
Dollar change
Percentage change
TELA TELA Bio Inc daily Stock Chart
IndexRUT P/E- EPS (ttm)-1.67 Insider Own30.12% Shs Outstand24.49M Perf Week-3.32%
Market Cap136.37M Forward P/E- EPS next Y-1.15 Insider Trans4.59% Shs Float17.23M Perf Month-4.98%
Income-40.30M PEG- EPS next Q-0.46 Inst Own47.15% Short Float5.84% Perf Quarter2.22%
Sales63.15M P/S2.16 EPS this Y25.34% Inst Trans17.14% Short Ratio6.30 Perf Half Y0.91%
Book/sh0.58 P/B9.48 EPS next Y24.34% ROA-61.70% Short Interest1.01M Perf Year-49.91%
Cash/sh1.51 P/C3.67 EPS next 5Y- ROE-459.89% 52W Range4.23 - 11.19 Perf YTD-16.47%
Dividend Est.- P/FCF- EPS past 5Y5.17% ROI-73.20% 52W High-50.58% Beta1.04
Dividend TTM- Quick Ratio3.23 Sales past 5Y49.61% Gross Margin68.97% 52W Low30.58% ATR (14)0.32
Dividend Ex-Date- Current Ratio4.13 EPS Y/Y TTM37.33% Oper. Margin-71.62% RSI (14)47.85 Volatility4.18% 5.96%
Employees227 Debt/Eq2.87 Sales Y/Y TTM40.03% Profit Margin-63.82% Recom1.00 Target Price14.20
Option/ShortYes / Yes LT Debt/Eq2.83 EPS Q/Q63.26% Payout- Rel Volume0.22 Prev Close5.63
Sales Surprise1.74% EPS Surprise52.95% Sales Q/Q39.42% EarningsMay 09 AMC Avg Volume159.54K Price5.53
SMA20-5.07% SMA504.82% SMA200-11.60% Trades Volume35,444 Change-1.78%
Date Action Analyst Rating Change Price Target Change
May-31-22Initiated Lake Street Buy $17
Dec-03-19Initiated Piper Jaffray Overweight
Dec-03-19Initiated JMP Securities Mkt Outperform
Dec-03-19Initiated Jefferies Buy
Dec-03-19Initiated Canaccord Genuity Buy
Jun-04-24 04:05PM
May-20-24 04:03PM
May-13-24 11:01AM
May-10-24 04:05PM
10:15AM Loading…
May-09-24 04:05PM
May-02-24 04:10PM
Apr-25-24 07:00AM
Apr-15-24 07:00AM
Apr-08-24 07:00AM
Mar-22-24 09:46AM
Mar-21-24 08:53PM
05:30PM Loading…
Mar-20-24 07:00AM
Feb-29-24 07:00AM
Feb-23-24 04:05PM
Jan-19-24 04:05PM
Dec-15-23 04:05PM
Dec-05-23 07:00AM
Nov-16-23 07:00AM
Nov-12-23 12:20PM
Nov-10-23 04:05PM
Nov-09-23 04:05PM
Oct-26-23 07:00AM
04:05PM Loading…
Sep-18-23 04:05PM
Aug-16-23 07:00AM
Aug-11-23 10:03AM
Aug-10-23 09:18AM
Aug-09-23 06:05PM
Aug-04-23 04:02PM
Jul-26-23 07:00AM
Jul-06-23 10:09AM
Jun-18-23 07:51PM
Jun-15-23 07:00AM
May-25-23 07:00AM
May-21-23 10:30AM
May-19-23 07:00AM
May-12-23 07:44AM
May-11-23 05:25PM
May-09-23 07:00AM
May-08-23 04:30PM
May-02-23 07:00AM
Apr-30-23 08:26AM
Apr-28-23 06:47PM
Apr-27-23 07:00AM
Apr-18-23 11:00PM
Apr-03-23 06:14AM
Mar-29-23 07:00AM
Mar-24-23 07:15AM
Mar-23-23 07:00AM
Mar-22-23 06:01AM
Mar-21-23 05:15PM
Mar-16-23 07:00AM
Feb-28-23 07:00AM
Feb-24-23 04:02PM
Feb-21-23 07:00AM
Feb-14-23 07:00AM
Jan-20-23 04:05PM
Jan-09-23 07:00AM
Dec-23-22 05:46AM
Dec-21-22 07:00AM
Dec-09-22 04:02PM
Nov-21-22 07:00AM
Nov-12-22 07:42AM
Nov-09-22 05:25PM
Nov-03-22 07:00AM
Oct-28-22 04:05PM
Oct-27-22 07:00AM
Oct-26-22 07:00AM
Oct-24-22 10:24AM
Sep-01-22 07:00AM
Aug-23-22 04:01PM
Aug-19-22 10:52AM
Aug-18-22 04:01PM
Aug-16-22 12:01PM
Aug-15-22 10:20PM
Aug-10-22 10:30PM
Aug-05-22 07:00AM
Aug-04-22 07:00AM
Jul-29-22 04:01PM
Jul-27-22 07:00AM
Jul-20-22 07:00AM
Jul-08-22 06:45AM
Jun-24-22 08:52AM
Jun-23-22 11:02AM
TELA Bio, Inc. is a commercial stage medical technology company, which focuses on the design, development, and market of tissue reinforcement materials. The company was founded by Antony Koblish and Maarten Persenaire on April 17, 2012 and is headquartered in Malvern, PA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Firestone Gregory A.Chief Business OfficerDec 05 '23Buy5.652,60014,68835,511Dec 07 04:02 PM
KOBLISH ANTONYChief Executive OfficerNov 14 '23Buy4.5411,00049,976303,634Nov 14 08:01 PM
Cuca RobertoCOO and CFONov 14 '23Buy4.4910,00044,93862,371Nov 14 08:02 PM
Last Close
Jun 13 04:00PM ET
Dollar change
Percentage change
ETON Eton Pharmaceuticals Inc daily Stock Chart
Index- P/E107.40 EPS (ttm)0.03 Insider Own5.34% Shs Outstand25.69M Perf Week-0.27%
Market Cap93.25M Forward P/E13.44 EPS next Y0.27 Insider Trans0.00% Shs Float24.32M Perf Month0.00%
Income0.91M PEG- EPS next Q0.00 Inst Own28.07% Short Float0.22% Perf Quarter-18.61%
Sales34.30M P/S2.72 EPS this Y112.50% Inst Trans6.71% Short Ratio0.89 Perf Half Y-8.56%
Book/sh0.60 P/B6.02 EPS next Y5300.00% ROA3.34% Short Interest0.05M Perf Year-4.97%
Cash/sh0.65 P/C5.60 EPS next 5Y- ROE6.83% 52W Range2.42 - 5.81 Perf YTD-17.12%
Dividend Est.- P/FCF15.86 EPS past 5Y63.71% ROI5.89% 52W High-37.52% Beta1.30
Dividend TTM- Quick Ratio1.43 Sales past 5Y11165.96% Gross Margin66.24% 52W Low50.00% ATR (14)0.15
Dividend Ex-Date- Current Ratio1.59 EPS Y/Y TTM114.58% Oper. Margin1.58% RSI (14)51.88 Volatility3.23% 3.52%
Employees30 Debt/Eq0.33 Sales Y/Y TTM40.71% Profit Margin2.66% Recom1.00 Target Price9.00
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q69.77% Payout- Rel Volume0.28 Prev Close3.63
Sales Surprise-0.42% EPS Surprise33.33% Sales Q/Q50.19% EarningsMay 09 AMC Avg Volume61.71K Price3.63
SMA200.23% SMA503.13% SMA200-10.91% Trades Volume17,220 Change0.00%
Date Action Analyst Rating Change Price Target Change
May-06-24Initiated Craig Hallum Buy $8
Oct-14-21Resumed B. Riley Securities Buy $10
Jan-04-21Reiterated H.C. Wainwright Buy $20 → $15
Sep-20-19Initiated B. Riley FBR Buy $13.50
Jun-10-19Initiated H.C. Wainwright Buy $15
May-10-24 10:11AM
May-09-24 04:01PM
May-01-24 04:05PM
Apr-30-24 11:21AM
04:30PM Loading…
Apr-29-24 04:30PM
Mar-22-24 02:20AM
Mar-15-24 03:10PM
Mar-14-24 08:55PM
Feb-29-24 04:01PM
08:19AM Loading…
Feb-26-24 08:19AM
Feb-21-24 06:50AM
Feb-02-24 06:50AM
Jan-16-24 07:52AM
Nov-11-23 11:09AM
Nov-09-23 04:01PM
Oct-30-23 06:50AM
Oct-23-23 05:16AM
Oct-18-23 08:00AM
Oct-04-23 06:50AM
Sep-22-23 12:04PM
Sep-20-23 09:40AM
Sep-12-23 08:50AM
Aug-25-23 11:36AM
Aug-23-23 06:50AM
09:15AM Loading…
Aug-16-23 09:15AM
Aug-13-23 07:52AM
Aug-11-23 12:44PM
Aug-10-23 05:40PM
Aug-08-23 10:50AM
Aug-01-23 04:05PM
Jul-17-23 04:05PM
Jul-15-23 08:40AM
Jun-28-23 06:50AM
May-16-23 11:35AM
May-11-23 05:35PM
May-10-23 06:50AM
May-03-23 04:05PM
Apr-19-23 11:22AM
Mar-22-23 07:17AM
Mar-18-23 02:03AM
Mar-16-23 05:25PM
Mar-15-23 06:50AM
Mar-07-23 04:05PM
Feb-08-23 12:00PM
Feb-05-23 07:30AM
Jan-31-23 08:00AM
Jan-25-23 10:00AM
Jan-24-23 12:26PM
Jan-23-23 11:01AM
Jan-12-23 10:34AM
Jan-11-23 07:27AM
Nov-23-22 12:37PM
Nov-22-22 12:45PM
Nov-16-22 10:33AM
Nov-10-22 05:45PM
Nov-02-22 04:05PM
Oct-18-22 04:05PM
Sep-27-22 09:05AM
Sep-13-22 09:00AM
Aug-30-22 04:05PM
Aug-11-22 05:35PM
Aug-08-22 10:00AM
Aug-04-22 10:00AM
Aug-02-22 08:00AM
Jul-18-22 08:09AM
Jun-24-22 09:45AM
Jun-13-22 12:28PM
May-13-22 09:08AM
May-12-22 05:15PM
May-10-22 05:45PM
May-05-22 07:25PM
May-03-22 04:02PM
Apr-12-22 10:03AM
Apr-11-22 04:01PM
Mar-16-22 04:02PM
Mar-14-22 07:00AM
Eton Pharmaceuticals, Inc. engages in the development, acquisition, and commercialization of prescription drug products. Its products include Biorphen, Alaway Preservative Free, zonisamide oral suspension, topiramate oral suspension, lamotrigine for oral suspension, cysteine injection, and ephedrine ready-to-use injection. The company was founded in April 2017 and is headquartered in Deer Park, IL.